TMC435350 + ritonavir

TMC435350 + ritonavir is an investigational **oral combination regimen** of **TMC435350**, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and **ritonavir**, a potent CYP3A inhibitor and HIV-1 protease inhibitor. TMC435350 (also known as simeprevir), when used alone, selectively targets and inhibits the HCV NS3/4A protease, a critical enzyme in HCV replication. Ritonavir is included in the combination to *boost* the plasma levels of TMC435350 (via inhibition of CYP3A-mediated metabolism), thereby potentially enhancing its antiviral effect and pharmacokinetic properties. The primary known indication is HCV infection; studies were in early-phase clinical trials assessing pharmacokinetics, safety, and tolerability in healthy volunteers[2].